4.3 Article

Bile Acid Sequestrants for Lipid and Glucose Control

Journal

CURRENT DIABETES REPORTS
Volume 10, Issue 1, Pages 70-77

Publisher

CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-009-0087-5

Keywords

Bile acid receptor; Bile acid sequestrant; Cholesterol; Glucose control; Lipid control; Type 2 diabetes mellitus

Funding

  1. Daiichi Sankyo, Inc
  2. GlaxoSmithKline
  3. Novo Nordisk
  4. Takeda Pharmaceuticals
  5. Medtronic
  6. Merck
  7. Xoma
  8. Tethys
  9. Bristol-Myers Squibb
  10. AstraZeneca
  11. Pfizer
  12. sanofi-aventis
  13. Eli Lilly
  14. US National Institutes of Health
  15. American Diabetes Association

Ask authors/readers for more resources

Bile acids are generated in the liver and are traditionally recognized for their regulatory role in multiple metabolic processes including bile acid homeostasis, nutrient absorption, and cholesterol homeostasis. Recently, bile acids emerged as signaling molecules that, as ligands for the bile acid receptors farnesoid X receptor (FXR) and TGR5, activate and integrate multiple complex signaling pathways involved in lipid and glucose metabolism. Bile acid sequestrants are pharmacologic molecules that bind to bile acids in the intestine resulting in the interruption of bile acid homeostasis and, consequently, reduction in low-density lipoprotein cholesterol levels in hypercholesterolemia. Bile acid sequestrants also reduce glucose levels and improve glycemic control in persons with type 2 diabetes mellitus (T2DM). This article examines the mechanisms by which bile acid-mediated activation of FXR and TGR5 signaling pathways regulate lipid and glucose metabolism and the potential implications for bile acid sequestrant-mediated regulation of lipid and glucose levels in T2DM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available